Test Price
450 AEDโ Home Collection Available
MUM1 Immunohistochemistry (IHC) Test in UAE | 450 AED | DHA-Licensed Facility
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 15189-Accredited IHC Processing with automated MUM1/IRF4 monoclonal antibody staining protocols.
Premium Logistics
Secure Medical Courier Solid Tissue Specimen Retrieval โ FFPE blocks and biopsy slides transported under temperature-controlled conditions.
Clinical Guidance
Telephonic Post-Test Clinical Correlation Discussion with DHA-Licensed Pathologist โ interpretation aligned with WHO 2022 Haematolymphoid Classification.
Insurance & Billing
Direct Billing Verification via WhatsApp: +971 54 548 8731
Price: 450 AED | Turnaround Time: 5โ7 Business Days
Test Overview & Methodology
The MUM1 (Multiple Myeloma Oncogene 1 / IRF4) Immunohistochemistry Test is a high-specificity tissue-based biomarker assay that detects IRF4 protein expression in formalin-fixed paraffin-embedded (FFPE) biopsy sections. This test serves as a critical differentiating tool for B-cell lymphoma subtyping and plasma cell neoplasm confirmation. MUM1 positivity is particularly informative in classifying the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma, guiding targeted therapy decisions.
| Parameter | Our MUM1 IHC Test (DHA Facility) | Standard Hospital IHC Panel |
|---|---|---|
| Precision / Antibody Specificity | MUM1/IRF4 Monoclonal Antibody (Clone MUM1p) โ validated per CAP/ASH guidelines | Often generic B-cell panel without MUM1-specific subtyping resolution |
| Detection Method | Automated IHC Staining Platform with DAB Chromogen & LC-MS/MS Correlation Capability | Manual or semi-automated IHC with limited molecular correlation |
| Turnaround Time (TAT) | 5โ7 Business Days (FFPE block or biopsy slide) | Typically 10โ14 Days for comprehensive IHC reporting |
| Price Transparency | 450 AED โ all-inclusive | Variable; often 600โ900 AED with add-on charges |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor
Specialist Diagnostic Radiology ยท DHA Registration ID: 61713011
"The MUM1 IHC stain is a cornerstone in modern haematopathology, but it must never be interpreted in isolation. A positive MUM1 result gains its true clinical meaning only when correlated with the full histomorphological picture, complementary markers (CD20, CD138, BCL6, Ki-67), and the patient's complete clinical history. I strongly advise all patients and referring physicians to discuss these results within a multidisciplinary tumour board context before making any therapeutic decisions."
Clinical Advisory: Medication & Result Interpretation
โ Important Clinical Notice
Do not discontinue any prescribed medication or alter your treatment regimen based on MUM1 IHC results without consulting your treating oncologist or haematologist. This biomarker test is one component of a comprehensive diagnostic workup and does not independently dictate therapeutic changes.
Exclusion Criteria & Emergency Red Flags
Specimen Rejection Criteria
- Inadequately fixed tissue (fixation time less than 6 hours in 10% neutral buffered formalin)
- Crushed, cauterized, or necrotic biopsy specimens with less than 10% viable tumour cellularity
- Decalcified tissue processed with strong acids (may destroy MUM1 antigenicity)
- FFPE blocks older than 5 years without antigen retrieval validation
- Missing or incomplete surgical pathology report and clinical history
Patient Safety โ Urgent Clinical Signs
- Rapidly enlarging lymph nodes with B-symptoms (fever, night sweats, >10% weight loss) โ seek immediate oncology evaluation
- Unexplained hypercalcemia or renal impairment with suspected plasma cell dyscrasia
- Pathologic fractures or spinal cord compression symptoms in known or suspected myeloma
- Progressive neurological deficits in patients with known B-cell lymphoma
If you experience any of the above symptoms, seek emergency medical attention immediately. This test is a diagnostic aid; it does not replace urgent clinical assessment.
Patient FAQ & Clinical Guidance
1. What does the MUM1 Immunohistochemistry test actually detect, and why has my oncologist ordered it?
The MUM1 IHC test detects IRF4 protein expression within tumour cells to differentiate between specific subtypes of B-cell lymphomas and plasma cell neoplasms with high precision. Your oncologist has likely ordered this test to distinguish diffuse large B-cell lymphoma (DLBCL) subtypes or to confirm a suspected plasma cell dyscrasia when standard histology alone is inconclusive. MUM1 positivity is particularly informative in classifying the activated B-cell (ABC) subtype of DLBCL, which carries distinct prognostic and therapeutic implications. The results guide targeted therapy selection and enrolment eligibility for clinical trials.
2. How should I prepare for the MUM1 IHC tissue test, and is there any risk involved?
No patient preparation is required for the MUM1 IHC itself because the analysis is performed on previously collected biopsy tissue rather than on the patient directly. The biopsy procedure that obtained your tissue sample would have been performed earlier by your surgeon or interventional radiologist under their specific preparation guidelines. There is zero additional risk from the IHC staining process โ it is a laboratory procedure conducted exclusively on the excised tissue block. However, you must ensure your referring physician has submitted the complete histopathology report and clinical history alongside the tissue specimen to enable accurate interpretation.
3. What does a positive MUM1 result mean for my diagnosis and treatment prognosis?
A positive MUM1 IHC result indicates that your tumour cells express the IRF4 transcription factor, which is characteristic of certain lymphoid malignancies including the activated B-cell subtype of DLBCL, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, and plasma cell neoplasms like multiple myeloma. This finding helps your oncologist refine the pathological classification and may influence the choice of first-line chemotherapy or targeted biologic therapy. Importantly, MUM1 positivity alone does not determine your overall prognosis โ its significance depends entirely on the complete immunophenotypic panel, molecular genetic findings, and your individual clinical parameters such as age, performance status, and disease stage.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 4 of 2016 on Medical Liability
Full adherence to clinical testing safety and patient consent requirements. All tissue handling and diagnostic procedures follow established medical liability standards for patient protection.
Federal Law No. 2 of 2019 โ Health ICT
Complete compliance with the use of information and communication technology in health fields. All electronic health records and test reports are managed under strict health data governance rules.
Federal Decree-Law No. 45 of 2021 (PDPL)
All patient-identifiable histopathology data, genomic correlates, and test results are encrypted and stored in full compliance with the UAE Personal Data Protection Law. No data sharing occurs without explicit patient consent.
Clinical & Logistical Metadata
| Test Name | MUM1 Immunohistochemistry (IHC) Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5โ7 Business Days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Blocks or Biopsy Slides |
| Methodology Used | Immunohistochemistry (IHC) โ Automated platform with MUM1/IRF4 monoclonal antibody, DAB chromogen detection |
| ICD-10-CM Code | C83.3, C90.0, C91.9 |
| LOINC Code | 10520-7 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians